nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—UGT1A9—Irinotecan—colon cancer	0.304	0.438	CbGbCtD
Ezogabine—UGT1A1—Irinotecan—colon cancer	0.248	0.358	CbGbCtD
Ezogabine—CYP2A6—Fluorouracil—colon cancer	0.142	0.204	CbGbCtD
Ezogabine—Psychiatric symptom—Capecitabine—colon cancer	0.0122	0.0596	CcSEcCtD
Ezogabine—Nail discolouration—Capecitabine—colon cancer	0.0112	0.0548	CcSEcCtD
Ezogabine—Dysphasia—Capecitabine—colon cancer	0.00644	0.0315	CcSEcCtD
Ezogabine—NAT2—renal system—colon cancer	0.00626	0.126	CbGeAlD
Ezogabine—NAT2—Metapathway biotransformation—CHST4—colon cancer	0.0044	0.0839	CbGpPWpGaD
Ezogabine—UGT1A4—renal system—colon cancer	0.00403	0.0815	CbGeAlD
Ezogabine—Chromaturia—Capecitabine—colon cancer	0.00394	0.0192	CcSEcCtD
Ezogabine—UGT1A3—digestive system—colon cancer	0.00389	0.0786	CbGeAlD
Ezogabine—KCNQ5—vagina—colon cancer	0.00385	0.0779	CbGeAlD
Ezogabine—NAT2—liver—colon cancer	0.00382	0.0773	CbGeAlD
Ezogabine—Balance disorder—Fluorouracil—colon cancer	0.00368	0.018	CcSEcCtD
Ezogabine—Myoclonus—Vincristine—colon cancer	0.00359	0.0175	CcSEcCtD
Ezogabine—UGT1A9—renal system—colon cancer	0.00338	0.0683	CbGeAlD
Ezogabine—UGT1A4—digestive system—colon cancer	0.00331	0.0668	CbGeAlD
Ezogabine—Encephalopathy—Fluorouracil—colon cancer	0.00314	0.0153	CcSEcCtD
Ezogabine—Hypokinesia—Irinotecan—colon cancer	0.00311	0.0152	CcSEcCtD
Ezogabine—Nystagmus—Vincristine—colon cancer	0.00302	0.0148	CcSEcCtD
Ezogabine—UGT1A3—liver—colon cancer	0.0029	0.0586	CbGeAlD
Ezogabine—Nystagmus—Fluorouracil—colon cancer	0.00282	0.0138	CcSEcCtD
Ezogabine—UGT1A9—digestive system—colon cancer	0.00277	0.056	CbGeAlD
Ezogabine—UGT1A4—Metapathway biotransformation—CHST4—colon cancer	0.00266	0.0508	CbGpPWpGaD
Ezogabine—Balance disorder—Capecitabine—colon cancer	0.00257	0.0126	CcSEcCtD
Ezogabine—KCNQ5—lymph node—colon cancer	0.00249	0.0504	CbGeAlD
Ezogabine—UGT1A4—liver—colon cancer	0.00246	0.0498	CbGeAlD
Ezogabine—Myoclonus—Capecitabine—colon cancer	0.00234	0.0114	CcSEcCtD
Ezogabine—UGT1A1—renal system—colon cancer	0.00232	0.0468	CbGeAlD
Ezogabine—Raised liver function tests—Methotrexate—colon cancer	0.00227	0.0111	CcSEcCtD
Ezogabine—Dysarthria—Irinotecan—colon cancer	0.00222	0.0109	CcSEcCtD
Ezogabine—UGT1A3—Metapathway biotransformation—CHST4—colon cancer	0.00222	0.0422	CbGpPWpGaD
Ezogabine—Gait disturbance—Vincristine—colon cancer	0.00221	0.0108	CcSEcCtD
Ezogabine—UGT1A1—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.00219	0.0418	CbGpPWpGaD
Ezogabine—Encephalopathy—Capecitabine—colon cancer	0.00219	0.0107	CcSEcCtD
Ezogabine—Aphasia—Capecitabine—colon cancer	0.00217	0.0106	CcSEcCtD
Ezogabine—Gait disturbance—Irinotecan—colon cancer	0.00215	0.0105	CcSEcCtD
Ezogabine—Dysarthria—Fluorouracil—colon cancer	0.00213	0.0104	CcSEcCtD
Ezogabine—UGT1A9—liver—colon cancer	0.00206	0.0417	CbGeAlD
Ezogabine—NAT2—Metapathway biotransformation—CHST5—colon cancer	0.00202	0.0385	CbGpPWpGaD
Ezogabine—Coma—Vincristine—colon cancer	0.00197	0.00964	CcSEcCtD
Ezogabine—UGT1A1—digestive system—colon cancer	0.0019	0.0384	CbGeAlD
Ezogabine—Coma—Fluorouracil—colon cancer	0.00184	0.00899	CcSEcCtD
Ezogabine—Memory impairment—Capecitabine—colon cancer	0.00179	0.00876	CcSEcCtD
Ezogabine—Euphoric mood—Fluorouracil—colon cancer	0.00173	0.00845	CcSEcCtD
Ezogabine—Disorientation—Fluorouracil—colon cancer	0.00163	0.00798	CcSEcCtD
Ezogabine—Encephalopathy—Methotrexate—colon cancer	0.00163	0.00797	CcSEcCtD
Ezogabine—Aphasia—Methotrexate—colon cancer	0.00161	0.00789	CcSEcCtD
Ezogabine—Skin discolouration—Capecitabine—colon cancer	0.00156	0.00761	CcSEcCtD
Ezogabine—Amnesia—Fluorouracil—colon cancer	0.00156	0.0076	CcSEcCtD
Ezogabine—UGT1A1—Metapathway biotransformation—CHST4—colon cancer	0.00153	0.0292	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—CHST4—colon cancer	0.00153	0.0292	CbGpPWpGaD
Ezogabine—Osteoarthritis—Irinotecan—colon cancer	0.00153	0.00746	CcSEcCtD
Ezogabine—Urinary retention—Vincristine—colon cancer	0.00149	0.00728	CcSEcCtD
Ezogabine—Dysarthria—Capecitabine—colon cancer	0.00149	0.00727	CcSEcCtD
Ezogabine—Osteoarthritis—Fluorouracil—colon cancer	0.00146	0.00714	CcSEcCtD
Ezogabine—Gait disturbance—Capecitabine—colon cancer	0.00144	0.00704	CcSEcCtD
Ezogabine—Coordination abnormal—Capecitabine—colon cancer	0.00143	0.007	CcSEcCtD
Ezogabine—UGT1A1—liver—colon cancer	0.00141	0.0286	CbGeAlD
Ezogabine—CYP2A6—vagina—colon cancer	0.00141	0.0286	CbGeAlD
Ezogabine—Neutropenia—Vincristine—colon cancer	0.00127	0.00619	CcSEcCtD
Ezogabine—Dysuria—Vincristine—colon cancer	0.00127	0.00619	CcSEcCtD
Ezogabine—Dysphagia—Fluorouracil—colon cancer	0.00126	0.00617	CcSEcCtD
Ezogabine—UGT1A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.00126	0.024	CbGpPWpGaD
Ezogabine—Neutropenia—Irinotecan—colon cancer	0.00123	0.00603	CcSEcCtD
Ezogabine—UGT1A4—Metapathway biotransformation—CHST5—colon cancer	0.00122	0.0233	CbGpPWpGaD
Ezogabine—CYP2A6—liver—colon cancer	0.00119	0.0241	CbGeAlD
Ezogabine—Skin discolouration—Methotrexate—colon cancer	0.00116	0.00567	CcSEcCtD
Ezogabine—Infestation NOS—Fluorouracil—colon cancer	0.00113	0.0055	CcSEcCtD
Ezogabine—Infestation—Fluorouracil—colon cancer	0.00113	0.0055	CcSEcCtD
Ezogabine—Dysarthria—Methotrexate—colon cancer	0.00111	0.00541	CcSEcCtD
Ezogabine—Amnesia—Capecitabine—colon cancer	0.00109	0.00531	CcSEcCtD
Ezogabine—Increased appetite—Capecitabine—colon cancer	0.00109	0.00531	CcSEcCtD
Ezogabine—Hallucination—Vincristine—colon cancer	0.00108	0.00527	CcSEcCtD
Ezogabine—Urinary tract disorder—Vincristine—colon cancer	0.00107	0.00523	CcSEcCtD
Ezogabine—Urethral disorder—Vincristine—colon cancer	0.00106	0.00519	CcSEcCtD
Ezogabine—UGT1A3—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.00105	0.02	CbGpPWpGaD
Ezogabine—Diplopia—Capecitabine—colon cancer	0.00102	0.00499	CcSEcCtD
Ezogabine—Osteoarthritis—Capecitabine—colon cancer	0.00102	0.00499	CcSEcCtD
Ezogabine—Visual impairment—Irinotecan—colon cancer	0.00102	0.00497	CcSEcCtD
Ezogabine—UGT1A3—Metapathway biotransformation—CHST5—colon cancer	0.00102	0.0194	CbGpPWpGaD
Ezogabine—UGT1A9—Irinotecan Pathway—APC—colon cancer	0.00101	0.0193	CbGpPWpGaD
Ezogabine—UGT1A1—Irinotecan Pathway—APC—colon cancer	0.00101	0.0193	CbGpPWpGaD
Ezogabine—Urinary retention—Capecitabine—colon cancer	0.000971	0.00475	CcSEcCtD
Ezogabine—Alopecia—Vincristine—colon cancer	0.000958	0.00468	CcSEcCtD
Ezogabine—Coma—Methotrexate—colon cancer	0.000957	0.00468	CcSEcCtD
Ezogabine—Mental disorder—Vincristine—colon cancer	0.00095	0.00464	CcSEcCtD
Ezogabine—Liver function test abnormal—Capecitabine—colon cancer	0.000943	0.00461	CcSEcCtD
Ezogabine—Alopecia—Irinotecan—colon cancer	0.000933	0.00456	CcSEcCtD
Ezogabine—Alopecia—Fluorouracil—colon cancer	0.000893	0.00437	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000891	0.017	CbGpPWpGaD
Ezogabine—Muscle spasms—Irinotecan—colon cancer	0.000883	0.00432	CcSEcCtD
Ezogabine—Influenza—Capecitabine—colon cancer	0.000883	0.00431	CcSEcCtD
Ezogabine—Dysphagia—Capecitabine—colon cancer	0.000883	0.00431	CcSEcCtD
Ezogabine—Ill-defined disorder—Irinotecan—colon cancer	0.000853	0.00417	CcSEcCtD
Ezogabine—Vertigo—Vincristine—colon cancer	0.000848	0.00414	CcSEcCtD
Ezogabine—Leukopenia—Vincristine—colon cancer	0.000845	0.00413	CcSEcCtD
Ezogabine—Vision blurred—Fluorouracil—colon cancer	0.000829	0.00405	CcSEcCtD
Ezogabine—Malaise—Irinotecan—colon cancer	0.000829	0.00405	CcSEcCtD
Ezogabine—Vertigo—Irinotecan—colon cancer	0.000826	0.00403	CcSEcCtD
Ezogabine—Neutropenia—Capecitabine—colon cancer	0.000825	0.00403	CcSEcCtD
Ezogabine—Dysuria—Capecitabine—colon cancer	0.000825	0.00403	CcSEcCtD
Ezogabine—Syncope—Irinotecan—colon cancer	0.000824	0.00403	CcSEcCtD
Ezogabine—Leukopenia—Irinotecan—colon cancer	0.000822	0.00402	CcSEcCtD
Ezogabine—Loss of consciousness—Irinotecan—colon cancer	0.000808	0.00395	CcSEcCtD
Ezogabine—Weight increased—Capecitabine—colon cancer	0.000803	0.00393	CcSEcCtD
Ezogabine—Leukopenia—Fluorouracil—colon cancer	0.000788	0.00385	CcSEcCtD
Ezogabine—Infestation NOS—Capecitabine—colon cancer	0.000787	0.00385	CcSEcCtD
Ezogabine—Infestation—Capecitabine—colon cancer	0.000787	0.00385	CcSEcCtD
Ezogabine—Discomfort—Irinotecan—colon cancer	0.000773	0.00378	CcSEcCtD
Ezogabine—Infection—Vincristine—colon cancer	0.000765	0.00374	CcSEcCtD
Ezogabine—Osteoarthritis—Methotrexate—colon cancer	0.00076	0.00372	CcSEcCtD
Ezogabine—Confusional state—Irinotecan—colon cancer	0.000756	0.0037	CcSEcCtD
Ezogabine—Nervous system disorder—Vincristine—colon cancer	0.000755	0.00369	CcSEcCtD
Ezogabine—Thrombocytopenia—Vincristine—colon cancer	0.000754	0.00368	CcSEcCtD
Ezogabine—Haematuria—Capecitabine—colon cancer	0.00075	0.00367	CcSEcCtD
Ezogabine—Infection—Irinotecan—colon cancer	0.000745	0.00364	CcSEcCtD
Ezogabine—Hyperhidrosis—Vincristine—colon cancer	0.000744	0.00364	CcSEcCtD
Ezogabine—Hepatobiliary disease—Capecitabine—colon cancer	0.000744	0.00364	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.00074	0.0141	CbGpPWpGaD
Ezogabine—Discomfort—Fluorouracil—colon cancer	0.00074	0.00362	CcSEcCtD
Ezogabine—Shock—Irinotecan—colon cancer	0.000738	0.00361	CcSEcCtD
Ezogabine—Nervous system disorder—Irinotecan—colon cancer	0.000735	0.00359	CcSEcCtD
Ezogabine—Thrombocytopenia—Irinotecan—colon cancer	0.000734	0.00359	CcSEcCtD
Ezogabine—Hyperhidrosis—Irinotecan—colon cancer	0.000725	0.00354	CcSEcCtD
Ezogabine—Confusional state—Fluorouracil—colon cancer	0.000724	0.00354	CcSEcCtD
Ezogabine—UGT1A1—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000723	0.0138	CbGpPWpGaD
Ezogabine—UGT1A9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000723	0.0138	CbGpPWpGaD
Ezogabine—Infection—Fluorouracil—colon cancer	0.000714	0.00349	CcSEcCtD
Ezogabine—Nervous system disorder—Fluorouracil—colon cancer	0.000704	0.00344	CcSEcCtD
Ezogabine—Thrombocytopenia—Fluorouracil—colon cancer	0.000703	0.00344	CcSEcCtD
Ezogabine—UGT1A1—Metapathway biotransformation—CHST5—colon cancer	0.000703	0.0134	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—CHST5—colon cancer	0.000703	0.0134	CbGpPWpGaD
Ezogabine—Liver function test abnormal—Methotrexate—colon cancer	0.000702	0.00343	CcSEcCtD
Ezogabine—Urinary tract disorder—Capecitabine—colon cancer	0.000698	0.00341	CcSEcCtD
Ezogabine—Oedema peripheral—Capecitabine—colon cancer	0.000696	0.0034	CcSEcCtD
Ezogabine—Urethral disorder—Capecitabine—colon cancer	0.000692	0.00338	CcSEcCtD
Ezogabine—Paraesthesia—Vincristine—colon cancer	0.000691	0.00338	CcSEcCtD
Ezogabine—Visual impairment—Capecitabine—colon cancer	0.000681	0.00333	CcSEcCtD
Ezogabine—Paraesthesia—Irinotecan—colon cancer	0.000673	0.00329	CcSEcCtD
Ezogabine—Dyspnoea—Irinotecan—colon cancer	0.000669	0.00327	CcSEcCtD
Ezogabine—Somnolence—Irinotecan—colon cancer	0.000667	0.00326	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Vincristine—colon cancer	0.000665	0.00325	CcSEcCtD
Ezogabine—Fatigue—Vincristine—colon cancer	0.000664	0.00324	CcSEcCtD
Ezogabine—Eye disorder—Capecitabine—colon cancer	0.00066	0.00323	CcSEcCtD
Ezogabine—Dyspepsia—Irinotecan—colon cancer	0.00066	0.00323	CcSEcCtD
Ezogabine—Constipation—Vincristine—colon cancer	0.000658	0.00322	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Irinotecan—colon cancer	0.000647	0.00316	CcSEcCtD
Ezogabine—Fatigue—Irinotecan—colon cancer	0.000647	0.00316	CcSEcCtD
Ezogabine—Paraesthesia—Fluorouracil—colon cancer	0.000645	0.00315	CcSEcCtD
Ezogabine—Constipation—Irinotecan—colon cancer	0.000641	0.00313	CcSEcCtD
Ezogabine—Dyspnoea—Fluorouracil—colon cancer	0.00064	0.00313	CcSEcCtD
Ezogabine—Somnolence—Fluorouracil—colon cancer	0.000638	0.00312	CcSEcCtD
Ezogabine—Dyspepsia—Fluorouracil—colon cancer	0.000632	0.00309	CcSEcCtD
Ezogabine—Alopecia—Capecitabine—colon cancer	0.000624	0.00305	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00062	0.00303	CcSEcCtD
Ezogabine—Mental disorder—Capecitabine—colon cancer	0.000619	0.00302	CcSEcCtD
Ezogabine—Feeling abnormal—Irinotecan—colon cancer	0.000618	0.00302	CcSEcCtD
Ezogabine—Malnutrition—Capecitabine—colon cancer	0.000615	0.00301	CcSEcCtD
Ezogabine—Neutropenia—Methotrexate—colon cancer	0.000614	0.003	CcSEcCtD
Ezogabine—Dysuria—Methotrexate—colon cancer	0.000614	0.003	CcSEcCtD
Ezogabine—Feeling abnormal—Fluorouracil—colon cancer	0.000592	0.00289	CcSEcCtD
Ezogabine—Muscle spasms—Capecitabine—colon cancer	0.000591	0.00289	CcSEcCtD
Ezogabine—Infestation NOS—Methotrexate—colon cancer	0.000586	0.00286	CcSEcCtD
Ezogabine—Infestation—Methotrexate—colon cancer	0.000586	0.00286	CcSEcCtD
Ezogabine—KCNQ2—Axon guidance—DCC—colon cancer	0.000584	0.0111	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—DCC—colon cancer	0.000584	0.0111	CbGpPWpGaD
Ezogabine—Vision blurred—Capecitabine—colon cancer	0.00058	0.00283	CcSEcCtD
Ezogabine—NAT2—Metabolism—CA7—colon cancer	0.000578	0.011	CbGpPWpGaD
Ezogabine—Tremor—Capecitabine—colon cancer	0.000576	0.00282	CcSEcCtD
Ezogabine—Ill-defined disorder—Capecitabine—colon cancer	0.000571	0.00279	CcSEcCtD
Ezogabine—Haematuria—Methotrexate—colon cancer	0.000559	0.00273	CcSEcCtD
Ezogabine—CYP2A6—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000557	0.0106	CbGpPWpGaD
Ezogabine—Malaise—Capecitabine—colon cancer	0.000555	0.00271	CcSEcCtD
Ezogabine—Hepatobiliary disease—Methotrexate—colon cancer	0.000554	0.00271	CcSEcCtD
Ezogabine—Vertigo—Capecitabine—colon cancer	0.000553	0.0027	CcSEcCtD
Ezogabine—Asthenia—Vincristine—colon cancer	0.000552	0.0027	CcSEcCtD
Ezogabine—Syncope—Capecitabine—colon cancer	0.000551	0.0027	CcSEcCtD
Ezogabine—Leukopenia—Capecitabine—colon cancer	0.00055	0.00269	CcSEcCtD
Ezogabine—Loss of consciousness—Capecitabine—colon cancer	0.00054	0.00264	CcSEcCtD
Ezogabine—Asthenia—Irinotecan—colon cancer	0.000538	0.00263	CcSEcCtD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—TYMS—colon cancer	0.000534	0.0102	CbGpPWpGaD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—colon cancer	0.000531	0.0101	CbGpPWpGaD
Ezogabine—Anxiety—Capecitabine—colon cancer	0.000522	0.00255	CcSEcCtD
Ezogabine—Urinary tract disorder—Methotrexate—colon cancer	0.000519	0.00254	CcSEcCtD
Ezogabine—Discomfort—Capecitabine—colon cancer	0.000517	0.00253	CcSEcCtD
Ezogabine—Urethral disorder—Methotrexate—colon cancer	0.000516	0.00252	CcSEcCtD
Ezogabine—Dry mouth—Capecitabine—colon cancer	0.000512	0.0025	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000512	0.00976	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000512	0.00976	CbGpPWpGaD
Ezogabine—Dizziness—Vincristine—colon cancer	0.000509	0.00249	CcSEcCtD
Ezogabine—Visual impairment—Methotrexate—colon cancer	0.000507	0.00248	CcSEcCtD
Ezogabine—Confusional state—Capecitabine—colon cancer	0.000506	0.00247	CcSEcCtD
Ezogabine—Infection—Capecitabine—colon cancer	0.000499	0.00244	CcSEcCtD
Ezogabine—Dizziness—Irinotecan—colon cancer	0.000496	0.00242	CcSEcCtD
Ezogabine—Shock—Capecitabine—colon cancer	0.000494	0.00241	CcSEcCtD
Ezogabine—Nervous system disorder—Capecitabine—colon cancer	0.000492	0.00241	CcSEcCtD
Ezogabine—Eye disorder—Methotrexate—colon cancer	0.000491	0.0024	CcSEcCtD
Ezogabine—Thrombocytopenia—Capecitabine—colon cancer	0.000491	0.0024	CcSEcCtD
Ezogabine—Rash—Vincristine—colon cancer	0.000485	0.00237	CcSEcCtD
Ezogabine—Hyperhidrosis—Capecitabine—colon cancer	0.000485	0.00237	CcSEcCtD
Ezogabine—Dermatitis—Vincristine—colon cancer	0.000485	0.00237	CcSEcCtD
Ezogabine—Dizziness—Fluorouracil—colon cancer	0.000475	0.00232	CcSEcCtD
Ezogabine—Rash—Irinotecan—colon cancer	0.000473	0.00231	CcSEcCtD
Ezogabine—Dermatitis—Irinotecan—colon cancer	0.000472	0.00231	CcSEcCtD
Ezogabine—Alopecia—Methotrexate—colon cancer	0.000465	0.00227	CcSEcCtD
Ezogabine—Mental disorder—Methotrexate—colon cancer	0.000461	0.00225	CcSEcCtD
Ezogabine—Malnutrition—Methotrexate—colon cancer	0.000458	0.00224	CcSEcCtD
Ezogabine—Nausea—Vincristine—colon cancer	0.000457	0.00224	CcSEcCtD
Ezogabine—Rash—Fluorouracil—colon cancer	0.000453	0.00221	CcSEcCtD
Ezogabine—Dermatitis—Fluorouracil—colon cancer	0.000452	0.00221	CcSEcCtD
Ezogabine—Paraesthesia—Capecitabine—colon cancer	0.000451	0.0022	CcSEcCtD
Ezogabine—Dyspnoea—Capecitabine—colon cancer	0.000447	0.00219	CcSEcCtD
Ezogabine—Nausea—Irinotecan—colon cancer	0.000445	0.00218	CcSEcCtD
Ezogabine—Dyspepsia—Capecitabine—colon cancer	0.000442	0.00216	CcSEcCtD
Ezogabine—KCNQ4—Neuronal System—BRAF—colon cancer	0.000433	0.00827	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—BRAF—colon cancer	0.000433	0.00827	CbGpPWpGaD
Ezogabine—Gastrointestinal disorder—Capecitabine—colon cancer	0.000433	0.00212	CcSEcCtD
Ezogabine—Fatigue—Capecitabine—colon cancer	0.000433	0.00211	CcSEcCtD
Ezogabine—Vision blurred—Methotrexate—colon cancer	0.000431	0.00211	CcSEcCtD
Ezogabine—Constipation—Capecitabine—colon cancer	0.000429	0.0021	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	0.000429	0.00817	CbGpPWpGaD
Ezogabine—Nausea—Fluorouracil—colon cancer	0.000427	0.00208	CcSEcCtD
Ezogabine—Ill-defined disorder—Methotrexate—colon cancer	0.000425	0.00208	CcSEcCtD
Ezogabine—UGT1A9—PPAR Alpha Pathway—CCND1—colon cancer	0.000422	0.00805	CbGpPWpGaD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—colon cancer	0.000418	0.00798	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	0.000417	0.00795	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—DCC—colon cancer	0.000416	0.00794	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—DCC—colon cancer	0.000416	0.00794	CbGpPWpGaD
Ezogabine—Feeling abnormal—Capecitabine—colon cancer	0.000414	0.00202	CcSEcCtD
Ezogabine—Malaise—Methotrexate—colon cancer	0.000413	0.00202	CcSEcCtD
Ezogabine—Vertigo—Methotrexate—colon cancer	0.000411	0.00201	CcSEcCtD
Ezogabine—Leukopenia—Methotrexate—colon cancer	0.00041	0.002	CcSEcCtD
Ezogabine—Discomfort—Methotrexate—colon cancer	0.000385	0.00188	CcSEcCtD
Ezogabine—Confusional state—Methotrexate—colon cancer	0.000377	0.00184	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	0.000373	0.0071	CbGpPWpGaD
Ezogabine—Infection—Methotrexate—colon cancer	0.000371	0.00181	CcSEcCtD
Ezogabine—Nervous system disorder—Methotrexate—colon cancer	0.000366	0.00179	CcSEcCtD
Ezogabine—Thrombocytopenia—Methotrexate—colon cancer	0.000366	0.00179	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.000365	0.00697	CbGpPWpGaD
Ezogabine—Hyperhidrosis—Methotrexate—colon cancer	0.000361	0.00177	CcSEcCtD
Ezogabine—Asthenia—Capecitabine—colon cancer	0.00036	0.00176	CcSEcCtD
Ezogabine—KCNQ3—L1CAM interactions—SRC—colon cancer	0.000359	0.00685	CbGpPWpGaD
Ezogabine—KCNQ2—L1CAM interactions—SRC—colon cancer	0.000359	0.00685	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	0.000356	0.00679	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—HNF4A—colon cancer	0.00035	0.00668	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—HNF4A—colon cancer	0.00035	0.00668	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CA7—colon cancer	0.00035	0.00668	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CHST5—colon cancer	0.00035	0.00668	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—ODC1—colon cancer	0.00035	0.00668	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	0.000346	0.00661	CbGpPWpGaD
Ezogabine—UGT1A9—PPAR Alpha Pathway—MYC—colon cancer	0.000339	0.00646	CbGpPWpGaD
Ezogabine—Paraesthesia—Methotrexate—colon cancer	0.000335	0.00164	CcSEcCtD
Ezogabine—Dyspnoea—Methotrexate—colon cancer	0.000333	0.00163	CcSEcCtD
Ezogabine—Somnolence—Methotrexate—colon cancer	0.000332	0.00162	CcSEcCtD
Ezogabine—Dizziness—Capecitabine—colon cancer	0.000332	0.00162	CcSEcCtD
Ezogabine—Dyspepsia—Methotrexate—colon cancer	0.000329	0.00161	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Methotrexate—colon cancer	0.000323	0.00158	CcSEcCtD
Ezogabine—Fatigue—Methotrexate—colon cancer	0.000322	0.00157	CcSEcCtD
Ezogabine—Rash—Capecitabine—colon cancer	0.000316	0.00155	CcSEcCtD
Ezogabine—Dermatitis—Capecitabine—colon cancer	0.000316	0.00155	CcSEcCtD
Ezogabine—KCNQ3—L1CAM interactions—EGFR—colon cancer	0.000315	0.006	CbGpPWpGaD
Ezogabine—KCNQ2—L1CAM interactions—EGFR—colon cancer	0.000315	0.006	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	0.00031	0.00591	CbGpPWpGaD
Ezogabine—Feeling abnormal—Methotrexate—colon cancer	0.000308	0.0015	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.000304	0.00579	CbGpPWpGaD
Ezogabine—Nausea—Capecitabine—colon cancer	0.000298	0.00146	CcSEcCtD
Ezogabine—UGT1A3—Metabolism—CA7—colon cancer	0.000291	0.00555	CbGpPWpGaD
Ezogabine—Asthenia—Methotrexate—colon cancer	0.000268	0.00131	CcSEcCtD
Ezogabine—Dizziness—Methotrexate—colon cancer	0.000247	0.00121	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	0.000246	0.00469	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	0.000246	0.00469	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	0.000239	0.00456	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	0.000239	0.00456	CbGpPWpGaD
Ezogabine—Rash—Methotrexate—colon cancer	0.000236	0.00115	CcSEcCtD
Ezogabine—Dermatitis—Methotrexate—colon cancer	0.000235	0.00115	CcSEcCtD
Ezogabine—KCNQ3—Neuronal System—BRAF—colon cancer	0.000234	0.00446	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—BRAF—colon cancer	0.000234	0.00446	CbGpPWpGaD
Ezogabine—Nausea—Methotrexate—colon cancer	0.000222	0.00108	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	0.000214	0.00408	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	0.000214	0.00408	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ODC1—colon cancer	0.000212	0.00405	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CHST5—colon cancer	0.000212	0.00405	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.00021	0.004	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.00021	0.004	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CA7—colon cancer	0.000201	0.00384	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CA7—colon cancer	0.000201	0.00384	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—HRAS—colon cancer	0.000199	0.0038	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—HRAS—colon cancer	0.000199	0.0038	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—PPARG—colon cancer	0.000187	0.00357	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—colon cancer	0.000183	0.0035	CbGpPWpGaD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—TP53—colon cancer	0.000177	0.00338	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ODC1—colon cancer	0.000176	0.00336	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CHST5—colon cancer	0.000176	0.00336	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CA7—colon cancer	0.000155	0.00296	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—PPARG—colon cancer	0.000152	0.0029	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—PPARG—colon cancer	0.000152	0.0029	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—TGFB1—colon cancer	0.000148	0.00282	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—SRC—colon cancer	0.000136	0.00259	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—SRC—colon cancer	0.000136	0.00259	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—VEGFA—colon cancer	0.000132	0.00252	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—VEGFA—colon cancer	0.000132	0.00252	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—NRAS—colon cancer	0.000131	0.00249	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—NRAS—colon cancer	0.000131	0.00249	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	0.000126	0.00241	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—TGFB1—colon cancer	0.000123	0.00234	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—EP300—colon cancer	0.000123	0.00234	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ODC1—colon cancer	0.000122	0.00232	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CHST5—colon cancer	0.000122	0.00232	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ODC1—colon cancer	0.000122	0.00232	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CHST5—colon cancer	0.000122	0.00232	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	0.00012	0.00229	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—EGFR—colon cancer	0.000119	0.00227	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—EGFR—colon cancer	0.000119	0.00227	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—KRAS—colon cancer	0.000112	0.00214	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—KRAS—colon cancer	0.000112	0.00214	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—HRAS—colon cancer	0.000108	0.00205	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—HRAS—colon cancer	0.000108	0.00205	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—CTNNB1—colon cancer	0.000107	0.00204	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—CTNNB1—colon cancer	0.000107	0.00204	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—EP300—colon cancer	9.96e-05	0.0019	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—EP300—colon cancer	9.96e-05	0.0019	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—SRC—colon cancer	9.68e-05	0.00185	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—SRC—colon cancer	9.68e-05	0.00185	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—HRAS—colon cancer	9.55e-05	0.00182	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—HRAS—colon cancer	9.55e-05	0.00182	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—VEGFA—colon cancer	9.43e-05	0.0018	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—VEGFA—colon cancer	9.43e-05	0.0018	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CHST5—colon cancer	9.39e-05	0.00179	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ODC1—colon cancer	9.39e-05	0.00179	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—NRAS—colon cancer	9.31e-05	0.00178	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—NRAS—colon cancer	9.31e-05	0.00178	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—ABCB1—colon cancer	9.25e-05	0.00176	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—TYMS—colon cancer	9.09e-05	0.00173	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TGFB1—colon cancer	8.66e-05	0.00165	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TGFB1—colon cancer	8.66e-05	0.00165	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—TGFB1—colon cancer	8.49e-05	0.00162	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—TGFB1—colon cancer	8.49e-05	0.00162	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—EGFR—colon cancer	8.49e-05	0.00162	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—EGFR—colon cancer	8.49e-05	0.00162	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	8.26e-05	0.00158	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—KRAS—colon cancer	8.02e-05	0.00153	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—KRAS—colon cancer	8.02e-05	0.00153	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—HRAS—colon cancer	6.81e-05	0.0013	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—HRAS—colon cancer	6.81e-05	0.0013	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—TGFB1—colon cancer	6.55e-05	0.00125	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PPARG—colon cancer	6.44e-05	0.00123	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—AKT1—colon cancer	6.02e-05	0.00115	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—AKT1—colon cancer	6.02e-05	0.00115	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ABCB1—colon cancer	5.61e-05	0.00107	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—TYMS—colon cancer	5.51e-05	0.00105	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTGS2—colon cancer	5.06e-05	0.000966	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	5.03e-05	0.000959	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ABCB1—colon cancer	4.66e-05	0.000889	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—TYMS—colon cancer	4.58e-05	0.000873	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—EP300—colon cancer	4.21e-05	0.000803	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.96e-05	0.000755	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PPARG—colon cancer	3.9e-05	0.000744	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.29e-05	0.000628	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PPARG—colon cancer	3.24e-05	0.000618	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ABCB1—colon cancer	3.22e-05	0.000614	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ABCB1—colon cancer	3.22e-05	0.000614	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—TYMS—colon cancer	3.16e-05	0.000603	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—TYMS—colon cancer	3.16e-05	0.000603	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CA—colon cancer	3.12e-05	0.000594	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTGS2—colon cancer	3.07e-05	0.000585	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—EP300—colon cancer	2.55e-05	0.000487	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTGS2—colon cancer	2.55e-05	0.000486	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—AKT1—colon cancer	2.55e-05	0.000485	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ABCB1—colon cancer	2.48e-05	0.000473	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TYMS—colon cancer	2.44e-05	0.000465	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.43e-05	0.000464	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PPARG—colon cancer	2.24e-05	0.000427	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PPARG—colon cancer	2.24e-05	0.000427	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—EP300—colon cancer	2.12e-05	0.000405	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CA—colon cancer	1.89e-05	0.00036	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTGS2—colon cancer	1.76e-05	0.000336	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTGS2—colon cancer	1.76e-05	0.000336	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PPARG—colon cancer	1.73e-05	0.000329	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CA—colon cancer	1.57e-05	0.000299	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—AKT1—colon cancer	1.54e-05	0.000294	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—EP300—colon cancer	1.47e-05	0.000279	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—EP300—colon cancer	1.47e-05	0.000279	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTGS2—colon cancer	1.36e-05	0.000259	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—AKT1—colon cancer	1.28e-05	0.000244	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—EP300—colon cancer	1.13e-05	0.000215	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CA—colon cancer	1.08e-05	0.000207	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CA—colon cancer	1.08e-05	0.000207	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—AKT1—colon cancer	8.86e-06	0.000169	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—AKT1—colon cancer	8.86e-06	0.000169	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CA—colon cancer	8.36e-06	0.000159	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—AKT1—colon cancer	6.83e-06	0.00013	CbGpPWpGaD
